Breaking News

Hoth Therapeutics, WuXi STA Ink API and Drug Product Pact

WuXi STA to provide process development and manufacturing of the API and formulation of drug product for development and commercialization of HT-KIT.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hoth Therapeutics, Inc., a biopharmaceutical company, has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing of the API and formulation of drug product for the continued development and commercialization of HT-KIT, a new molecular entity (NME) morpholino oligonucleotide therapy in development for targeting mast cell-derived cancers (hematological neoplasm, or mast cell leukemia and anaphylaxis).   The agreements...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters